VNRX Stock Analysis: Buy, Sell, or Hold?
VNRX - VolitionRX Limited Common Stock
$0.72
-0.08 (-10.20%)
▼
5d:
-28.19%
30d:
-47.2%
90d:
-72.59%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
10d
Get Alerted When VNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VNRX is down 28.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VNRX is down 28.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VNRX is currently trading at $0.72, which is considered oversold relative to its 30-day fair value range of $1.00 to $1.38. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.6) compared to its historical average (0.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VNRX is in a uptrend. Immediate support is located at $0.69, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 10.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.97 (+2262.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VNRX is in a uptrend. Immediate support is located at $0.69, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 10.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.97 (+2262.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.00 -
$1.38
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.2%)
- BULLISH: Trading 2262.6% below Wall St target ($16.97)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -28.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.00 -
$1.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.69
Resistance Level
$1.19
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.62
Wall Street Target
$16.97
(+2262.6%)
Revenue Growth (YoY)
299.8%
PE vs Historical
-0.6 vs 0.6
CHEAP
Share & Embed Analysis
Last updated: August 02, 2026 5:09 AM ET
Data refreshes hourly during market hours. Next update: 6:09 AM
Data refreshes hourly during market hours. Next update: 6:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$72 | 55 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$86 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 57 HOLD |
